Nuwellis, Inc.

The momentum for this stock is not very good. Nuwellis, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Nuwellis, Inc..
Log in to see more information.

News

Head-To-Head Analysis: Nuwellis (NASDAQ:NUWE) and Pixie Dust Technologies (NASDAQ:PXDT)
Head-To-Head Analysis: Nuwellis (NASDAQ:NUWE) and Pixie Dust Technologies (NASDAQ:PXDT)

Zolmax Pixie Dust Technologies (NASDAQ:PXDT - Get Free Report) and Nuwellis (NASDAQ:NUWE - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two...\n more…

Nuwellis (NASDAQ:NUWE) & Pixie Dust Technologies (NASDAQ:PXDT) Financial Comparison
Nuwellis (NASDAQ:NUWE) & Pixie Dust Technologies (NASDAQ:PXDT) Financial Comparison

Ticker Report Nuwellis (NASDAQ:NUWE - Get Free Report) and Pixie Dust Technologies (NASDAQ:PXDT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two...\n more…

Q3 2024 EPS Estimates for Nuwellis, Inc. (NASDAQ:NUWE) Raised by Roth Capital
Q3 2024 EPS Estimates for Nuwellis, Inc. (NASDAQ:NUWE) Raised by Roth Capital

Zolmax Nuwellis, Inc. (NASDAQ:NUWE - Free Report) - Equities research analysts at Roth Capital boosted their Q3 2024 earnings per share estimates for shares of Nuwellis in a report issued on Wednesday...\n more…

Nuwellis, Inc. (NASDAQ:NUWE) to Post Q3 2024 Earnings of ($0.88) Per Share, Roth Capital Forecasts
Nuwellis, Inc. (NASDAQ:NUWE) to Post Q3 2024 Earnings of ($0.88) Per Share, Roth Capital Forecasts

Ticker Report Nuwellis, Inc. (NASDAQ:NUWE - Free Report) - Analysts at Roth Capital raised their Q3 2024 earnings per share (EPS) estimates for Nuwellis in a research note issued to investors on Wednesday, August...\n more…

FY2027 EPS Estimates for Nuwellis, Inc. Decreased by Roth Capital (NASDAQ:NUWE)
FY2027 EPS Estimates for Nuwellis, Inc. Decreased by Roth Capital (NASDAQ:NUWE)

Ticker Report Nuwellis, Inc. (NASDAQ:NUWE - Free Report) - Analysts at Roth Capital cut their FY2027 earnings per share (EPS) estimates for shares of Nuwellis in a research note issued on Wednesday, August 28th...\n more…

New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy
New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy

Globe Newswire MINNEAPOLIS, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to...\n more…